How can transADMET™ models improve your R&D productivity?
- Pharmaceuticals. Only a small fraction of pharmaceutical compounds entering Phase I studies obtain market approval. A major reason for failure is that current preclinical models are often poorly predictive of the situation in man. Given profound interspecies differences in the levels and functions of proteins involved in drug absorption, distribution, metabolism, excretion and toxicology (ADMET), this inability to predict human response is perhaps not surprising.
Chemicals and Agrochemicals. Compounds cannot be evaluated in clinical studies therefore the assessment of the risk to man is based largely on in vitro studies, animal studies or epidemiological studies. Given species differences and the difficulty in extrapolating in vitro studies to in vivo, the development of “humanised” animal models which more closely reflect human response is an important new approach to human risk assessment.
Through the collaborative efforts of CXR Biosciences and TaconicArtemis, as part of an ITI Life Sciences research program, a broad platform of humanised mouse models have been created to address the challenges of predicting human response during in vivo compound testing. The transADMET™ models are packaged in three panels representing critical pathways in compound metabolism and disposition:
In each of these panels key murine genes have been exchanged for their human counterparts. The panels also contain associated knockout models.
Contract Research Services exclusively available at CXR
The first commercial colonies of Receptor Panel animals have now been established, making several lines immediately available for studies. These animals can be accessed on a contract research basis exclusively at CXR Biosciences, or bought off-the-shelf from our partner Taconic.
The Cytochrome P450 and Drug Transporter panels are currently in development and are not yet commercially available.
